Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

<p>Patient demographics and tumor characteristics at baseline and at surgery, by randomized treatment group.</p>

Đã lưu trong:

Chi tiết về thư mục
Tác giả chính:	Nigel Bundred (15046233) (author)
Tác giả khác:	Nuria Porta (15029895) (author), Adrian Murray Brunt (15046236) (author), Angela Cramer (5870894) (author), Andrew Hanby (25460) (author), Abeer M. Shaaban (15046239) (author), Emad A. Rakha (7957955) (author), Anne Armstrong (15045410) (author), Ramsey I. Cutress (15046242) (author), David Dodwell (15046245) (author), Marie A. Emson (15046248) (author), Abigail Evans (7421527) (author), Sue M. Hartup (15046251) (author), Kieran Horgan (15030513) (author), Sarah E. Miller (15046254) (author), Stuart A. McIntosh (11368948) (author), James P. Morden (7594370) (author), Jay Naik (15046257) (author), Sankaran Narayanan (15046260) (author), Jane Ooi (15046263) (author), Anthony I. Skene (15046266) (author), David A. Cameron (6277425) (author), Judith M. Bliss (8827107) (author)
Được phát hành:	2025
Những chủ đề:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Biomarkers Prognostic biomarkers Breast Cancer Clinical Trial Results Phase II clinical trials Precision Medicine
Các nhãn:	Thêm thẻ Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Những quyển sách tương tự

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Bằng: Nigel Bundred (15046233)
Được phát hành: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Bằng: Nigel Bundred (15046233)
Được phát hành: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Bằng: Nigel Bundred (15046233)
Được phát hành: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Bằng: Nigel Bundred (15046233)
Được phát hành: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
Bằng: Ruiyun Zhang (17142498)
Được phát hành: (2025)

Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S13 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S7 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S8 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S9 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Table S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Table S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Bằng: Rohit Thummalapalli (17314483)
Được phát hành: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Bằng: Kala Visvanathan (14952973)
Được phát hành: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Bằng: Kala Visvanathan (14952973)
Được phát hành: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Bằng: Kala Visvanathan (14952973)
Được phát hành: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Bằng: Kala Visvanathan (14952973)
Được phát hành: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Bằng: Kala Visvanathan (14952973)
Được phát hành: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Bằng: Nam Q. Bui (14958210)
Được phát hành: (2025)

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Bằng: Ulka N. Vaishampayan (15051039)
Được phát hành: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Bằng: Ulka N. Vaishampayan (15051039)
Được phát hành: (2025)

Cannot write session to /tmp/vufind_sessions/sess_vicdl6i2c8tjdtpuo766jeku6e